Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44237   clinical trials with a EudraCT protocol, of which   7338   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001617-27
    Sponsor's Protocol Code Number:IVA_01_337_HSSC_15_001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-07-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-001617-27
    A.3Full title of the trial
    A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis.
    Estudio aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de evaluación preliminar de la eficacia de IVA337 en el tratamiento de la esclerosis sistémica cutánea difusa.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to investigate the efficacy and safety of a new compound for the treatment of diffuse systemic sclerosis, called IVA337. Patients in the trial will be randomly allocated to either the new treatment or a placebo and will be unaware of which treatment they are receiving.
    Un ensayo clínico para investigar la eficacia y seguridad de un nuevo compuesto para el tratamiento de la esclerosis sistémica difusa, llamado IVA337. Los pacientes en el ensayo serán asignados al azar al tratamiento nuevo o a placebo y no conocerán el tratamiento que estén recibiendo.
    A.3.2Name or abbreviated title of the trial where available
    IVA337 SSC POC
    A.4.1Sponsor's protocol code numberIVA_01_337_HSSC_15_001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorInventiva SAS
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInventiva SAS
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationInventiva
    B.5.2Functional name of contact pointManager
    B.5.3 Address:
    B.5.3.1Street Address50 rue de Dijon
    B.5.3.2Town/ cityDaix
    B.5.3.3Post code21121
    B.5.3.4CountryFrance
    B.5.4Telephone number+34917081250
    B.5.5Fax number+33380447561
    B.5.6E-mailmari-carmen.delatte@inventivapharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/129/14
    D.3 Description of the IMP
    D.3.1Product nameIVA337
    D.3.2Product code IVA337
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIVA337
    D.3.9.1CAS number 927961-18-0
    D.3.9.2Current sponsor codeIVA337
    D.3.9.3Other descriptive name1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID
    D.3.9.4EV Substance CodeSUB176833
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Systemic sclerosis (scleroderma) (SSc) is a chronic connective tissue disorder of unknown aetiology characterized by widespread microvascular damage and excessive deposition of collagen in the skin and internal organs.
    La esclerosis sistémica (esclerodermia) (SSc) es una enfermedad crónica del tejido conjuntivo de causa desconocida que se caracteriza por daño microvascular difuso y acumulación excesiva de colágeno en la piel y los órganos internos.
    E.1.1.1Medical condition in easily understood language
    Systemic sclerosis is caused by a build up of fibrous and collagen deposits in the skin and internal organs leading to damage to internal organs.
    La esclerosis sistémica es causada por una acumulación de depósitos fibrosos y de colágeno en la piel y órganos internos que conducen a daños en los órganos internos.
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10012941
    E.1.2Term Diffuse scleroderma
    E.1.2System Organ Class 100000004859
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10074034
    E.1.2Term Generalised scleroderma
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate in patients suffering from diffuse cutaneous SSc (DcSSc) the effect of 800mg and 1200mg IVA337 daily on the skin compared to placebo. The modified Rodnan Skin Score (MRSS) will be used to determine the changes in skin.
    El objetivo principal de este estudio es evaluar el efecto sobre la piel de 800 mg y 1.200 mg diarios de IVA337 en pacientes con SSc cutánea difusa (DcSSc), en comparación con placebo. Para determinar los cambios en la piel, se utilizará la escala cutánea de Rodnan modificada (MRSS).
    E.2.2Secondary objectives of the trial
    Secondary objectives include additional efficacy evaluations (details in the protocol), assessment of adverse events (AEs), and determination of population PK parameters of IVA337 in patients.
    Los objetivos secundarios son evaluaciones adicionales de la eficacia (detalles en el protocolo), evaluación de acontecimientos adversos (AAs) y determinación de parámetros PK de población de IVA337 en pacientes.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Systemic sclerosis according to ACR/EULAR 2013 criteria
    - Diffuse cutaneous SSc subset (LeRoy?s criteria)
    - Diagnosis within the past 3 years as defined by the first non-Raynaud?s symptom
    - MRSS between 10 and 25
    - Aged between 18 and 75 years
    - Informed consent documented by signature
    - Esclerosis sistémica según los criterios ACR/EULAR 2013 (van de Hoogen 2013)
    - Subgrupo de SSc cutánea difusa según los criterios de LeRoy
    - Diagnóstico en los 3 años anteriores definido por el primer síntoma no Raynaud
    - MRSS entre 10 y 25
    - Edad entre 18 y 75 años
    - Documento de consentimiento informado firmado
    E.4Principal exclusion criteria
    ? Unstable treatment with corticosteroids or immunosuppressive agents (stable therapy for more than 3 months with prednisone ? 10 mg, methotrexate? 20 mg/w, azathioprine ? 150 mg/d, mycofenolate mofetil ? 2g/d, or leflunomide ? 20 mg/d is acceptable)
    ? Cyclophosphamide during the past 6 months
    ? Requirement of IV prostanoids for critical ischemia or pulmonary hypertension in the last 3 months
    ? Renal insufficiency defined by a creatinine clearance of less than 30 ml/min and/or past/current renal crisis
    ? Hepatic impairment i.e. primary biliary cirrhosis and unexplained persistent liver function abnormality,
    ? Gallbladder disease
    ? Severe cardiac (LVEF <45%) and/or pulmonary disease (FVC < 50% or pulmonary hypertension proven by right heart catheterisation)
    ? History of heart failure, symptomatic coronary artery disease, significant ventricular tachyarrhythmia, stent placement, coronary artery bypass surgery, and/or myocardial infarction.
    ? Recipient of solid organ transplant
    ? Gastrointestinal involvement preventing oral administration of study drug
    ? Chronic infections, positive serology for infection with hepatitis B or C.
    ? Pregnancy, Lactation. Woman of childbearing potential unwilling to use a medically acceptable form of birth control
    ? History of malignancy within the last 5 years, except for resected basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ cervical cancer
    ? A recent history of alcohol or drug abuse, non-compliance with other medical therapies
    ? Participation in a clinical study involving another investigational drug or device within 4 weeks before the Pre-treatment Visit
    ? Laboratory parameters at the pre-treatment visit showing any of the following abnormal results: transaminases > 2x the upper limit of normal (ULN) and/or bilirubin > 2x ULN; neutrophil count < 1,500/mm3; platelet count < 100,000/mm3; haemoglobin < 9 g/dL
    ? Contraindications to the class of drugs under study (PPAR agonists), e.g. known hypersensitivity or allergy to class of drugs or the investigational product (see IB 2015)
    ? Any condition or treatment, which in the opinion of the investigator, places the subject at unacceptable risk as a patient in the trial (Please consider the precautions and warnings described in the IB 2015.)
    ? Tratamiento inestable con corticoesteroides o inmunosupresores (se acepta el tratamiento estable durante más de 3 meses con ? 10 mg de prednisona, ? 20 mg/semana de metotrexato, ? 150 mg/día de azatioprina, ? 2g/día de micofenolato mofetilo o ? 20 mg/día de leflunomida)
    ? Ciclofosfamida durante los últimos 3 meses
    ? Necesidad de prostanoides i.v. para hipertensión pulmonar en los últimos 3 meses
    ? Insuficiencia renal definida por aclaramiento de creatinina inferior a 30 ml/min y/o crisis renal anterior/actual
    ? Insuficiencia hepática: cirrosis biliar primaria y anomalía de la función hepática persistente e inexplicada
    ? Enfermedad de la vesícula biliar
    ? Enfermedad cardíaca (LVEF <45%) y/o pulmonar grave (FVC < 50% o hipertensión pulmonar demostrada mediante cateterización del corazón derecho)
    ? Antecedentes de insuficiencia cardíaca, arteriopatía coronaria sintomática, taquiarritmia ventricular importante, colocación de un stent, intervención de bypass coronario y/o infarto de miocardio.
    ? Receptor de trasplante de órgano sólido
    ? Afectación gastrointestinal que impide la administración oral del fármaco del estudio
    ? Infección crónica, serología positiva para hepatitis B o C.
    ? Embarazo, lactancia. Mujer en edad fértil que no desea utilizar un método anticonceptivo médicamente aceptable
    ? Antecedentes de cáncer en los últimos 5 años, excepto resección de carcinoma de células basales o escamosas, displasia cervical tratada o cáncer cervical in situ tratado
    ? Historia reciente de abuso de alcohol o drogas, incumplimiento de otros tratamientos médicos
    ? Participación en un estudio clínico con otro fármaco o producto sanitario en investigación en el plazo de 4 semanas antes de la visita de pretratamiento
    ? Parámetros de laboratorio en la visita de pretratamiento que indiquen alguno de los siguientes resultados anormales: transaminasas > 2 veces el límite superior de normalidad (LSN) y/o bilirrubina > 2 veces el LSN; neutrófilos < 1.500/mm3; plaquetas < 100.000/mm3; hemoglobina < 9 g/dl
    ? Contraindicaciones a la clase de fármacos en estudio (agonistas PPAR), por ej., hipersensibilidad o alergia conocida a la clase de fármacos o al producto en investigación (véase el MI 2015)
    ? Cualquier afección o tratamiento que, en opinión del investigador, sitúe al sujeto en una situación de riesgo inaceptable como paciente del ensayo (Ténganse en cuenta las precauciones y advertencias descritas en el MI 2015.)
    E.5 End points
    E.5.1Primary end point(s)
    Primary outcome is the mean change of the Modifed Rodnan Skin Score (MRSS) from baseline to week 48
    El criterio de valoración principal es el cambio medio de la MRSS en la semana 48 respecto al valor basal.
    E.5.1.1Timepoint(s) of evaluation of this end point
    48 weeks
    48 semanas
    E.5.2Secondary end point(s)
    EFFICACY
    ? MRSS response rates; improvers are defined by a reduction ?5 points and ?25 % of MRSS
    ? Overall progression of the disease: defined as absence of rescue therapy and absence of severe organ involvement (see definition below)
    ? Change in pulmonary function (FVC% predicted and cDLCO% predicted)
    ? Changes in patient reported outcomes (SHAQ, UCLA SCTC GIT, PROMIS29, SF36)
    ? Digital ulcer net burden (defined as total number of ulcers at a certain time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers
    ? Cochin Hand Function Scale
    ? Physician and patient global assessments of disease activity over the past week (VAS)
    ? Change in the Combined Response Index for Systemic Sclerosis (CRISS), consisting of five variables: MRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI score (from SHAQ patient reported outcome)
    ? Need for escape therapy (% patients)
    ? Severe organ involvement (% patients) defined by
    ? new renal crisis OR
    ? new or worsened clinically symptomatic and significant heart disease, considered secondary to DcSSc OR
    ? Relative decline in FVC % predicted by ? 10% or relative decline in FVC % predicted between 5 to < 10% with associated relative decline in DLCO % predicted by ? 15%, provided that the decline in FVC results in FVC <75% of predicted OR
    ? New or worsening of gastrointestinal disease requiring hospitalization or new requirement for parenteral nutrition OR
    ? Critical digital ischemia of the extremities promoting the necrosis or gangrene
    ? Active polyarthritis defined by tender joints > 8 and swollen joints > 6 OR
    ? New onset of tendon friction rubs
    SAFETY
    ? Frequency and type of AEs
    ? Lab tests: mean change and frequency of values outside the normal range
    OTHER
    ? Changes in Raynaud phenomenon (Raynaud?s condition score)
    ? Mean changes in activity biomarkers
    ? Population pharmacokinetics
    ? Follow-up: There is a follow-up visit to evaluate any changes that might occur within 12 weeks after completion of the treatment. The performed assessments listed in the Schedule of Study Procedures refer to safety and efficacy.
    EFICACIA
    ? Tasa de respuesta con la MRSS; las mejorías se definen por una reducción ?5 puntos y ?25 % en la MRSS
    ? Progresión global de la enfermedad: definida como la ausencia de tratamiento de rescate y ausencia de afectación orgánica grave (véase la definición más adelante)
    ? Cambio en la función pulmonar (FVC% prevista y cDLCO% prevista)
    ? Cambios en los resultados comunicados por el paciente (SHAQ, UCLA SCTC GIT, PROMIS29, SF36)
    ? Número neto de úlceras digitales (definido como el número total de úlceras en un tiempo determinado menos el número de úlceras en el momento basal) y proporción de pacientes que no presentan úlceras nuevas
    ? Escala de funcionalidad de las manos de Cochin
    ? Evaluaciones globales por el médico y el paciente de la actividad de la enfermedad (EAV) durante la semana anterior
    ? Cambio en el índice de respuesta combinado para la esclerosis sistémica (CRISS), que consta de cinco variables: MRSS, FVC% prevista, evaluaciones globales por el médico y el paciente e índice HAQ-DI (a partir de los resultados SHAQ comunicados por el paciente)
    ? Necesidad de tratamiento de rescate (% de pacientes)
    ? Afectación orgánica grave (% de pacientes) definida por
    ? nueva crisis renal, O
    ? nueva aparición o empeoramiento de cardiopatía clínicamente sintomática e importante, que se considera secundaria a la DcSSc, O
    ? Disminución relativa de la FVC% prevista ? 10% o disminución relativa de la FVC% prevista entre 5 y < 10% con disminución relativa asociada de DLCO% prevista ? 15%, siempre y cuando la disminución de la FVC dé lugar a FVC <75% de lo previsto, O
    ? Nueva aparición o empeoramiento de la enfermedad gastrointestinal que requiera hospitalización o necesite de nuevo nutrición parenteral, O
    ? Isquemia crítica de las extremidades que provoca necrosis y/o gangrena, O
    ? Poliartritis activa definida por > 8 articulaciones dolorosas a la palpación y > 6 articulaciones edematosas, O
    ? Nueva aparición de roces de fricción tendinosos
    SEGURIDAD
    ? Frecuencia y tipo de AAs
    ? Pruebas de laboratorio: cambio medio y frecuencia de valores por fuera del intervalo normal
    OTROS
    ? Cambios en el fenómeno de Raynaud (puntuación del fenómeno de Raynaud)
    ? Cambios medios en los biomarcadores de actividad
    ? Farmacocinética de población
    ? Seguimiento: Existe una visita de seguimiento para evaluar cualquier cambio que se pudiera producir en el plazo de 12 semanas después de la finalización del tratamiento. Las evaluaciones realizadas que figuran en el Calendario de actividades del estudio se refieren a la seguridad y a la eficacia.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the study at weeks, 2, 4, 8, 12, 16, 24, 28, 32, 40, 48, 60.
    Durante todo el estudio en las semanas, 2, 4, 8, 12, 16, 24, 28, 32, 40, 48, 60.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Switzerland
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last visit of last subject
    última vista del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 85
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state11
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 95
    F.4.2.2In the whole clinical trial 105
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    ninguno
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation EUSTAR
    G.4.3.4Network Country France
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-08-03
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-10-12
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA